UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 290,551 Shares of IDEXX Laboratories, Inc. $IDXX

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,076,429 shares of the company’s stock after purchasing an additional 290,551 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 1.34% of IDEXX Laboratories worth $452,046,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of IDEXX Laboratories by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock worth $4,139,001,000 after purchasing an additional 146,427 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after purchasing an additional 825,965 shares during the period. Invesco Ltd. lifted its stake in shares of IDEXX Laboratories by 0.5% in the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock worth $489,832,000 after purchasing an additional 5,418 shares during the period. Principal Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock worth $472,865,000 after purchasing an additional 414,802 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of IDEXX Laboratories by 59,810.7% in the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock worth $3,856,950,000 after purchasing an additional 916,898 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 7,143 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the transaction, the executive vice president directly owned 6,156 shares of the company’s stock, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 in the last 90 days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.4%

Shares of IDXX opened at $655.60 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The company has a 50 day simple moving average of $597.81 and a two-hundred day simple moving average of $509.91. The firm has a market cap of $52.45 billion, a P/E ratio of 54.59, a price-to-earnings-growth ratio of 4.23 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the firm posted $2.44 EPS. The company’s revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price objective on the stock. Leerink Partners increased their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a report on Monday, August 4th. BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Finally, JPMorgan Chase & Co. increased their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $649.44.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.